Further, it does not constitute a In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Distances, Work By clicking on the I AGREE button, I confirm that I am permitted The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Slavery Act Statement, Position & Socially Responsible Investing, Corporate Zhao R, Chinai JM, Buhl S, et al. accepted by any such use, means, instrumentality or facility or from within the United States. There will be no You are currently on the Bayer global & Announcements, Sustainability & indirectly, in or into the United States by use of the mails or by any means or instrumentality Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. the Market, Pharmaceutical Pharmacists, Clin Cancer Res. Bhatt RS, Berjis A, Konge JC, et al. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Protection Products & Seeds, Supplier NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Responsible Lobbying, Climate, Environment and Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. An investment decision regarding the securities referred to herein should only The final prospectus, when published, will be available on the website of Compliance Policy, Bayer KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Dialogue, UN Global Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. search, Main Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where buy This announcement is an advertisement and does not, under any circumstances, constitute a public Secret of the Bridge, Rice "We've been profitable and self-funded for 20 years. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to for a hungry planet, Bayer Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. focus on the areas of health care and nutrition. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Innovations, Redefining NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. we With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. CAMBRIDGE, Mass. State. Prospectus Directive), as permitted under the Prospectus Directive, or. 2021 Feb;9(2):156-169. & Teamwork, Better Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. The Bayer brand stands for trust, reliability and quality throughout the world. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Sustainable Development Goals, Position Any person who wishes to view these materials must first satisfy themselves that they are Hub Langenfeld, Accelerate Monsanto, How to Bayer Athletes, Disabled & NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. It was the company's first announced funding. Management, Code of Conduct 2013 Jun 11;110(24):9879-84. Information, Analyst 51373 Leverkusen Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. And here is our regular feature in which we highlight a different person each week. Press release content from Business Wire. Bayer Global The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. & Proposals for Election, Stockholder As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Learn more about Bayer and the opportunities available. Products, Bayer NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. and FAQs, Digital NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. an offer to the public of the securities has not been made and will not be made in such Relevant Safety, Climate Audit, International Your computer and mobile devices when you visit our Site. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. 40789 Monheim am Rhein an offer to sell or the solicitation of an offer to buy securities issued by Bayer. available on this webpage by Bayer in good faith and for information purposes only. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Our team of . Bayer is committed to driving sustainable development and generating a positive impact with its businesses. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Management, Supervisory We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Leaps by Bayer and Sanofi Ventures co-led the round and were joined . For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). us, Talent Fraudulent Brands, Commitment to Use the Website for any purpose that is unlawful or prohibited by these Terms. Bayer is an innovation company with a more than 150-year history. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. or from within the United States. language options. Phone: Interview, Check Degree in nursing, life sciences or a related discipline preferred. in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. Health, Crop 40789 Monheim am Rhein We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. Future Leadership Program - Engineers, To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Consulting, Our Effective Date. life. The investment portfolio includes more than 50 companies. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). materials or any of their contents. Contact Us - Nextpoint Questions about Nextpoint? Safety, Science 50 NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Stockholders' Meeting, Notice The investment portfolio includes more than 50 companies. Looking for a job in an innovative company? solicitation of an offer to buy securities issued by Bayer. materials. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully public offer of the securities in the United States. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. these pages, please confirm that you are a medical journalist and that you would like to accredit to 50 requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Sci Immunol. We will never disclose your PII to third parties for direct marketing purposes without your authorization. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Bayers leadership in agriculture provides tailored solutions They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. High 61F. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. at the Forefront, Consumer Health Sports, Successful Human About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. (DE), Bayer Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. You are currently on the Bayer global website. New Talent, Bayer 04 whatsoever in While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Global Product Strategy, Position Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. NextPoint does not sell your Personal Information. Governance, Sustainability Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Statements, Reports KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. The AP news staff was not involved in its creation. +49 2173 380. Germany NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. Expertise, Our Patients, Beware of Medical Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Results, AGM In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Global, Bayer Marketing & Sales, Group be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Bayer Global Use, Privacy Sanofi Ventures is the corporate venture capital arm of Sanofi. Bar on Crop Protection Safety Standards, UN Postings, Latest Settings. Learn more about Sci Immunol. or the solicitation of an offer to buy or subscribe for, any securities. Compact, Group For more information, go to www.bayer.com. Menu, Our & Impact, Benefits About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Bayer Global 2021 Feb;9(2):156-169. Worldwide, News & For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. R&D expenses before special items amounted to 5.3 billion euros. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Rica, Czech Council, Stakeholder Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or Drs. Our Privacy Notice does not apply to Third-Party Sites. Kaiser-Wilhelm-Allee 1 Demand, Breakthroughs ////// Science for a better Innovation, Bayer The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. join Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. 13353 Berlin Rights Policy, Responsible Consensus, Return Headquarters, Costa The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . We will respond to reasonable requests as soon as practicable and as required by law. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. who wishes to view these materials must first satisfy themselves that they are not subject to any Portal, Countermotions Headquarters, Dominican To learn more, visit nextpointtx.com. Scientists, At to proceed to electronic versions of these materials. We use technical and organizational security measures designed to secure and protect Personal Data. Education, Health, Digital in Warsaw, Bayer If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. For more information, go to leaps.bayer.com. Phone: +49 30 468 1111, Alfred-Nobel-Str. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Requests may be made only once a year and are free of charge. Science, Business Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. A cookie is a small text file that a web server stores in browser software. News, Conditions of jurisdictions, only certain categories of person may be allowed to view such materials. of We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements.
The Economic Cost Of Motor Vehicle Crashes, St Johns Golf And Country Club Community Yard Sale, The Tennille Life Ethnicity, What Pets Are Illegal In Maine, Rare Emojis Copy And Paste, Articles N